Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics?
AUTOR(ES)
Mannello, Ferdinando
FONTE
BioMed Central
RESUMO
Since its identification, much information has been obtained about prostate-specific antigen (PSA, or human glandular kallikrein 3 [hK3]), a kallikrein-like serine protease that is the most valuable tumour marker for the screening, diagnosis and management of human prostate carcinoma. Recently, it has become widely accepted that PSA is also present in many nonprostatic sources, casting doubts about the specificity of its tissue expression. Here we summarize the findings on the biomolecular expression of PSA in breast secretions, cells and tissues of healthy and diseased females. Although several studies have strongly suggested that the molecular forms of PSA seem to represent a potential tool for the risk assessment of breast cancer, recent reports have yielded conflicting results. Although several studies have suggested new biological function(s) for PSA in breast physiopathology, more studies are needed to enlist PSA unequivocally as an additional weapon in the anticancer armoury in breast cancer diagnostics.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=138688Documentos Relacionados
- Prostate-specific antigen in screening for prostate cancer.
- Urology: Prostate-Specific Antigen
- Expression of androgen receptor and prostate-specific antigen in male breast carcinoma
- Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?
- The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy
